BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Original Article
Year : 2026  |  Volume : 17  |  Issue : 3  |  Page : 8559-8562 Full Version
Inter-kingdom metabolic disparities at the human -fungal interface exploring unique fungal metabolites for selective antifungal targets & lab-based susceptibility markers
Int J Biol Med Res. 2026; 17(3): 8559-8562  |  DOI: 10.65048/ijbmr.2026.17.3.8559.1041
Dr. Atul Khajuria
Faculty of Allied & Healthcare Sciences, Rayat Bahra Professional University, Hoshiarpur, Punjab, India
Correspondence Address :
Dr. Atul Khajuria,
Dean, Faculty of Allied & Healthcare Sciences
Rayat Bahra Professional University, Hoshiarpur,
Punjab, India. E-mail: atulkhajuria83@gmail.com
Received: March 9, 2026 Accepted: May 20, 2026 Published: July 3, 2026

Abstract
Background: Fungal infections have emerged as a major global health challenge, particularly among immunocompromised individuals. Current antifungal therapies are limited by toxicity, resistance, and the close evolutionary relationship between fungi and humans. Unique metabolic pathways present in fungi but absent in humans represent promising targets for selective antifungal therapy. Methods: A literature-based analytical review and laboratory correlation framework were developed to evaluate fungal-specific metabolic pathways. Major pathways analyzed included ergosterol biosynthesis, fungal cell-wall polysaccharide metabolism, siderophore-mediated iron acquisition, and secondary metabolite production. Laboratory susceptibility markers were mapped against metabolic targets using published susceptibility testing methods including broth microdilution, metabolic assays, and molecular markers. Results: Several fungal metabolites were identified as promising antifungal targets including ergosterol intermediates, ?-1,3-glucan synthesis products, chitin derivatives, and siderophore compounds. These metabolites demonstrate strong interkingdom metabolic divergence. Laboratory markers such as ?-D-glucan levels, ergosterol quantification, and siderophore detection may provide measurable indicators of antifungal susceptibility and fungal metabolic activity. Conclusions: Inter-kingdom metabolic differences provide an important framework for identifying selective antifungal targets. Integration of metabolic biomarkers into laboratory susceptibility testing may improve antifungal stewardship and early therapeutic decision-making.
Keywords
Inter-kingdom metabolism, Fungal metabolites, Antifungal drug targets, Ergosterol biosynthesis, Fungal cell wall, Siderophores, Secondary metabolites, Antifungal resistance, Diagnostic biomarkers, Laboratory susceptibility testing

Introduction

Fungal infections represent an increasingly significant cause of morbidity and mortality worldwide, particularly among immunocompromised individuals and hospitalized patients. Recent global estimates suggest that invasive fungal diseases affect millions of individuals annually, with high mortality rates associated with systemic infections [1-7].

Pathogenic fungi such as Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans are responsible for the majority of life-threatening fungal infections in humans [9,10,15,39]. These organisms exploit host metabolic resources while deploying specialized biochemical pathways that enable survival within the host environment [5,28].

One of the major challenges in antifungal drug development arises from the eukaryotic nature of fungal cells, which share many structural and metabolic similarities with human cells [6,8]. Consequently, only a limited number of antifungal drug classes are currently available, and many exhibit significant toxicity or reduced efficacy due to emerging resistance [11-15,35].

An important strategy for identifying selective antifungal targets involves studying inter-kingdom metabolic disparities, defined as biochemical pathways that exist in fungi but are absent or substantially different in human cells [20-24]. Examples include fungal cell-wall biosynthesis, ergosterol metabolism, siderophore-mediated iron acquisition, and the synthesis of unique secondary metabolites [16-19,25].

Understanding these pathways not only supports antifungal drug discovery but also provides opportunities for the development of laboratory-based susceptibility markers that can improve the diagnosis and monitoring of fungal infections [26,30-35].

Materials and Method

1.1 Objectives

1.1.1 Primary Objective

To analyzemetabolic differences between humans and pathogenic fungi in order to identify fungal-specific metabolites that can serve as selective antifungal drug targets and laboratory susceptibility markers.

1.1.2 Specific Objectives

  1. To evaluate major fungal metabolic pathways including ergosterol biosynthesis, cell wall polysaccharide synthesis, siderophore-mediated iron acquisition, and secondary metabolite production.
  2. To identify metabolites unique to fungal physiology that can be exploited for selective antifungal drug development.
  3. To correlate fungal metabolic products with laboratory-based susceptibility markers and diagnostic assays.
  4. To assess the clinical significance of fungal metabolic biomarkers in the detection and monitoring of invasive fungal infections.
  5. To highlight potential novel metabolic targets that could improve antifungal therapy and reduce drug resistance.

2. Methods

2.1 Study Design

This investigation was conducted as a structured metabolic pathway analysis integrating data from microbiology, fungal biochemistry, and antifungal pharmacology literature [8,18,40].

Selection of Fungal Species

Common clinically relevant fungal pathogens were analysed:

  1. Candida albicans
  2. Aspergillus fumigatus
  3. Cryptococcus neoformans
  4. Candida auris

These organisms represent major etiological agents of invasive fungal infections [10,15,39].

Metabolic Pathway Analysis

Key fungal metabolic pathways were evaluated:

  1. Ergosterol biosynthesis [18,19]
  2. Cell wall polysaccharide synthesis [25]
  3. Iron acquisition pathways [14]
  4. Secondary metabolite production [28]
  5. Amino acid and nitrogen metabolism [40]

Laboratory Correlation

Metabolites from these pathways were correlated with available laboratory susceptibility tests, including:

  1. Broth microdilution assays [11]
  2. Metabolic biomarker assays [22]
  3. Enzyme activity tests
  4. Molecular detection techniques [38]
Results

3.1 Fungal-Specific Metabolic Pathways

Several metabolic pathways were found to be unique or significantly divergent in fungi compared with humans [8,18]

Table 1. Major Metabolic Differences Between Humans and Fungi

Metabolic Feature

Humans

Fungi

Clinical Significance

References

Membrane sterol

Cholesterol

Ergosterol

Target of azole and polyene drugs

[11,18,19]

Cell wall

Absent

Present

Target for echinocandins

[9,25]

Iron acquisition

Transferrin dependent

Siderophore mediated

Potential antifungal target

[14]

Polysaccharide synthesis

Limited

Extensive

Important for virulence

[15,25]

Secondary metabolites

Minimal

Diverse toxins and pigments

Diagnostic biomarkers

[28,40]

 

3.2 Ergosterol Biosynthesis as a Drug Target

The fungal cell membrane contains ergosterol, whereas human cells contain cholesterol. Inhibition of ergosterol synthesis disrupts membrane integrity [18,19,20].

Table 2. Key Enzymes in Ergosterol Biosynthesis

Enzyme

Function

Targeted Drug Class

References

Squalene epoxidase

Sterol precursor synthesis

Allylamines

[11,18,20]

Lanosterol demethylase

Ergosterol formation

Azoles

[11,18,19]

Erg3 enzyme

Sterol modification

Experimental inhibitors

[18,19]

Erg11 enzyme

Demethylation step

Azole antifungals

[18,19,13]

 

3.3 Cell Wall Metabolites

The fungal cell membrane contains ergosterol, whereas human cells contain cholesterol. Inhibition of ergosterol synthesis disrupts membrane integrity and fungal growth [18,19,20]

Table 3. Major Fungal Cell Wall Components

Component

Function

Diagnostic / Therapeutic Relevance

References

β-1,3-glucan

Structural support

Serum biomarker

[9,22,25]

Chitin

Mechanical strength

Target for chitin synthase inhibitors

[25]

Mannoproteins

Adhesion

Immune recognition

[17,27]

α-glucans

Virulence factor

Potential drug target

[15,28]

3.4 Iron Acquisition via Siderophores

Fungi produce specialized molecules known as siderophores that scavenge iron from the host environment [14].

Table 4. Common Fungal Siderophores

Siderophore

Producing Fungi

Biological Role

References

Ferricrocin

Aspergillus species

Iron storage

[14,15]

Triacetylfusarinine C

Aspergillus species

Iron transport

[14]

Rhizoferrin

Mucorales

Iron uptake

[14,40]

Coprogen

Various fungi

Iron scavenging

[14]

 

3.5 Secondary Metabolites

Fungal pathogens produce various secondary metabolites involved in virulence and host interaction [28].

Table 5. Important Fungal Secondary Metabolites

Metabolite

Fungal Source

Clinical Importance

References

Gliotoxin

Aspergillus fumigatus

Immunosuppression

[15,28]

Melanin

Cryptococcus neoformans

Protection from host immunity

[5,28]

Candidalysin

Candida albicans

Tissue damage

[28,34]

Fumagillin

Aspergillus species

Angiogenesis inhibition

[15,40]

 

3.6 Laboratory Susceptibility Markers

Several metabolites may serve as measurable markers for antifungal susceptibility [22,38].

Table 6. Potential Metabolic Susceptibility Markers

Marker

Detection Method

Clinical Utility

References

β-D-glucan

Serum assay

Diagnosis of invasive fungal infection

[22,38]

Ergosterol levels

Chromatography

Drug response monitoring

[18,20]

Siderophore production

Mass spectrometry

Virulence indicator

[14]

Chitin fragments

Enzyme assay

Fungal growth marker

[25]

 

Discussion

This analysis demonstrates that inter-kingdom metabolic disparities provide valuable insight into antifungal drug development. Fungal-specific biochemical pathways offer opportunities for selective targeting while minimizing toxicity to human cells.

The ergosterol pathway remains one of the most successful antifungal targets, exploited by azoles and polyenes. However, emerging resistance in pathogens such as Candida auris has highlighted the need for additional targets.[7]

Cell-wall biosynthesis represents another promising area. Agents targeting β-glucan synthesis have already shown success, but further exploration of chitin metabolism may expand therapeutic options.[8]

Iron acquisition mechanisms, particularly siderophore production in fungi like Aspergillus fumigatus, are emerging as potential antifungal targets and diagnostic markers.[9]

Integration of metabolic biomarkers into laboratory diagnostics may also improve antifungal susceptibility testing. Metabolite-based assays could provide rapid indicators of fungal growth and drug response compared with traditional culture methods.

Conclusions

Metabolic disparities between humans and fungi provide a powerful framework for antifungal drug discovery and laboratory diagnostics. Unique fungal metabolites such as ergosterol intermediates, β-glucans, siderophores, and virulence-associated secondary metabolites represent promising targets for selective therapy and susceptibility monitoring. Future research integrating metabolomics, molecular diagnostics, and antifungal pharmacology may significantly improve management of invasive fungal infections.

Future Perspectives

Future research should focus on integrating metabolomics, genomics, and molecular diagnostics to better understand fungal metabolic networks and their role in pathogenicity. Advances in high-throughput metabolite profiling and mass spectrometry-based diagnostics may allow rapid detection of fungal biomarkers in clinical samples. Additionally, exploring novel metabolic enzymes and pathways unique to fungi could facilitate the development of next-generation antifungal drugs with improved selectivity and reduced toxicity. The incorporation of metabolic biomarkers into routine laboratory susceptibility testing may also enable faster therapeutic decision-making and strengthen antifungal stewardship programs. Continued investigation of fungal metabolic diversity will therefore be essential for improving the diagnosis, treatment, and prevention of invasive fungal diseases.

References

[1]    Gordon D. Brown, David W. Denning, Neil A. R. Gow, Stuart M. Levitz, Mihai G. Netea, Theodore C. White. Hidden killers: human fungal infections. Science Translational Medicine. 2012;4(165):165rv13.
[2]    Friday Bongomin, Samuel Gago, Rita O. Oladele, David W. Denning. Global and multi-national prevalence of fungal diseases—estimate precision. Journal of Fungi. 2017;3(4):57.
[3]    Matthew C. Fisher, Nicholas J. Hawkins, Dominique Sanglard, Sarah J. Gurr. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739-742.
[4]    David W. Denning, Michael J. Bromley. Infectious disease: how to bolster the antifungal pipeline. Science. 2015;347(6229):1414-1416.
[5]    Arturo Casadevall, Claudia Coelho, Radames J. B. Cordero, QianruDragotakes, Eun Jung, Rahul Vij, Michelle P. Wear. The capsule of Cryptococcus neoformans. Virulence. 2019;10(1):822-831.
[6]    Bart Jan Kullberg, MaikenCavlingArendrup. Invasive candidiasis. New England Journal of Medicine. 2015;373(15):1445-1456.
[7]    David W. Denning. Global incidence and mortality of severe fungal disease. Lancet Infectious Diseases. 2024;24:e428-e438.
[8]    Joseph R. Perfect. The antifungal pipeline: a reality check. Nature Reviews Drug Discovery. 2017;16(9):603-616.
[9]    David S. Perlin. Echinocandin resistance in Candida. Clinical Infectious Diseases. 2015;61(S6):S612-S617.
[10]    Mary Ann Pfaller, David J. Diekema. Epidemiology of invasive candidiasis. Clinical Microbiology Reviews. 2007;20(1):133-163.
[11]    Frederick C. Odds, Alistair J. P. Brown, Neil A. R. Gow. Antifungal agents: mechanisms of action. Trends in Microbiology. 2003;11(6):272-279.
[12]    Paul E. Verweij, Erik Snelders, Gerrit H. J. Kema, Emilio Mellado, Willem J. G. Melchers. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infectious Diseases. 2009;9(12):789-795.
[13]    Emilio Mellado, Willem J. G. Melchers, Paul E. Verweij. Azole resistance in Aspergillus fumigatus: mechanisms and clinical implications. Future Microbiology. 2011;6(3):335-347.
[14]    Howard Haas. Iron acquisition in fungal pathogens. Nature Reviews Microbiology. 2014;12(9):659-671.
[15]    Jean-Paul Latgé, George Chamilos.Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews. 2019;33(1):e00140-18.
[16]    Leah E. Cowen, Dominique Sanglard, Stuart J. Howard, Paul D. Rogers, David S. Perlin. Mechanisms of antifungal drug resistance. Cold Spring Harbor Perspectives in Medicine. 2015;5(7):a019752.
[17]    Ramon A. Drummond, Chad Steele. Recent advances in antifungal immunity. Current Opinion in Microbiology.2018;40:1-6.
[18]    Lingyun Song, Sha Wang, Hang Zou, Xiaokang Yi, Shihan Jia, Rongpeng Li, Jinxing Song. Regulation of ergosterol biosynthesis in pathogenic fungi: opportunities for therapeutic development. Microorganisms. 2025;13(4):862. 
[19]    Daniel Eliaš, Nora TóthHervay, YvettaGbelská. Ergosterol biosynthesis and regulation impact antifungal resistance and virulence of Candida species. Stresses. 2024;4(4):641-662. 
[20]    Sanjay B. Rajput, Suresh M. Karuppayil. Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans. SpringerPlus.2013;2:26. 
[21]    Michael Hoenigl, Daniel Seidel, Rolf Sprute, Cristiano Cunha, Maurizio Oliverio, Gustavo H. Goldman. COVID-19 associated fungal infections. Nature Microbiology. 2022;7(8):1127-1140.
[22]    Zachary Freeman Weiss, Ana Leon, Sara Koo. The evolving landscape of fungal diagnostics. Journal of Fungi. 2021;7(2):127.
[23]    Manuel Bassetti, Daniele Roberto Giacobbe, Carina Agvald-Ohman. Invasive fungal diseases in adult ICU patients: consensus definitions. Intensive Care Medicine.2024;50:502-515.
[24]    William E. Dismukes, Peter G. Pappas, Jack D. Sobel. Clinical Mycology. Oxford University Press; 2003.
[25]    Carol A. Munro, Neil A. R. Gow. Chitin synthesis in human pathogenic fungi. Medical Mycology. 2001;39(1):41-53.
[26]    Leah E. Cowen. The evolution of fungal drug resistance. Annual Review of Microbiology.2008;62:309-338.
[27]    Judith Berman, Tamar Sudbery.Candida albicans: a molecular revolution built on lessons from budding yeast. Nature Reviews Genetics. 2002;3(12):918-930.
[28]    Anand S. Jhingran, George S. Deepe. Fungal virulence factors and host immunity. Cell Host & Microbe. 2016;19(5):627-637.
[29]    Gordon D. Brown, Mihai G. Netea. Exciting developments in the immunology of fungal infections. Cell Host & Microbe. 2012;11(5):422-424.
[30]    Ronan C. O’Meara, Leah E. Cowen. Hsp90-dependent regulation of antifungal drug resistance. Current Opinion in Microbiology.2014;20:11-17.
[31]    David W. Denning. Invasive aspergillosis. Clinical Infectious Diseases. 1998;26(4):781-805.
[32]    Paul E. Verweij, David W. Denning. The challenge of invasive fungal infections. Lancet.1997;349:119-123.
[33]    Kerry A. Marr, Paul D. Schlamm, Dimitrios P. Kontoyiannis. Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases.2004;39:797-802.
[34]    Richard A. Calderone, William A. Fonzi. Virulence factors of Candida albicans. Trends in Microbiology. 2001;9(7):327-335.
[35]    Daniel P. Kontoyiannis, Russell E. Lewis. Antifungal drug resistance of pathogenic fungi. Lancet.2002;359:1135-1144.
[36]    Matthew C. Fisher, Timothy R. Henk, Conrad J. Briggs. Emerging fungal threats to human health. Nature.2012;484:186-194.
[37]    Antonio Cassone, Antonio Casadevall. Recent progress in vaccines against fungal diseases. Current Opinion in Microbiology. 2012;15(4):427-433.
[38]    David S. Perlin, John E. Wiederhold. Culture-independent molecular diagnostics for fungal infections. Clinical Microbiology Reviews. 2017;30(2):529-560.
[39]    Anuradha Chowdhary, Jacques F. Meis, Cornelia Lass-Flörl.Candida auris: a rapidly emerging cause of hospital-acquired infections. Clinical Microbiology Reviews. 2017;30(2):529-563.
[40]    Joseph Heitman, Christina A. Cuomo, David A. Carter, Jennifer A. Perfect. The Fungal Kingdom. ASM Press; 2017.


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications